HOME > NEWS > Development of a new endovascular medical device

Development of a new endovascular medical device

Within the Collaboration Challenges program, Aortyx and the GEMAT group collaborate in the development and preclinical validation of a new endovascular medical device with localized and controlled release of anti-progression drugs for aneurysms.
Desarrollo dispositivo médico endovascular
Researchers Inés Moreno from Aortyx and Carles Bofill from the GEMAT group


The IQS spinoff Aortyx is developing new technology to treat aortic aneurysms, a life-threatening disease caused by the degeneration of the aortic wall. The aorta expands and loses mechanical strength, risking rupture or dissection, which is what makes aneurysms fatal. At present, this disease is not treated until it is very advanced, since both open and endovascular surgery have high rates of complications and mortality and often require subsequent operations again.

The aim of Aortyx is to revolutionize the treatment of this disease, changing the focus of the replacement of the tissue by a graft by focusing on a reinforcement of the existing tissue and the progressive stoppage of the aneurysm. To achieve this, the company aims to take advantage of the platform that it has already designed and patented, which is already in an advanced preclinical stage.


New Aortyx-GEMAT collaboration

Aortyx seeks to go a step further, collaborating again with the Materials Engineering Group (GEMAT) at the IQS School of Engineering, experts in biomaterials and the nanoencapsulation of drugs. Together, they are developing an advanced version of the patch in a new project with the main objective of the localized and controlled release of anti-aneurysm progression drugs, slightly modifying the original patch. The project is being funded by the Collaboration Challenges programme of the Ministry of Science and Innovation – State Research Agency, and has a duration of three years (2020-2023).

To achieve this main objective, the Aortyx-IQS team has established several technological challenges associated with the project, such as:

  1. Achieving new encapsulation and drug release systems based on polymeric nanoparticles.
  2. Developing new systems for attaching the nanoparticles to the original patch to achieve local release in the target tissue.
  3. Developing a manufacturing system for the patch-nanoparticles assembly that can be scalable, according to ISO/GMP standards.
  4. Validating the new medical device at the preclinical level.

The project is currently in its first year and has already achieved some of the objectives, such as the integration of a specific anti-aneurysm drug loaded within the nanoparticles that make up the new patch.


State R&D&i Programme – Collaboration Challenges

Within the state program aimed at Society’s Challenges, the objective of the call for Challenges-Collaboration is to support experimental development projects in cooperation between companies and research organizations in order to promote the development of new technologies, the application new ideas and techniques, and contribute to the creation of new products and services.


Salvador Borrós Gómez, PhD

Director of IQS - Head of GEMAT Group - Professor

Jordi Martorell López, PhD

Head of GEVAB Group - Assistant Professor



Grup d'Enginyeria de Materials

School of Engineering

Materials Engineering

Its activities focus on three main areas: the development of new functional materials, surface engineering and biomaterials.


Grup d'Enginyeria Vascular i Biomedicina Aplicada

School of Engineering

Vascular Engineering and Applied Biomedicine Group

GEVAB's main objective is to integrate knowledge from medicine, biology, chemistry, physics, mathematics and computing in order to provide solutions to clinical needs.



School of Engineering

Chemical & Synthetic Biology for Biotherapies

This group combines chemistry and synthetic biology to develop precision bio-nano-therapeutics based on smart proteins and to generate molecular systems that enable transport of therapeutics to the brain.


Dispositivo médico aneurisma

Desarrollo y validación preclínica de un dispositivo médico endovascular con liberación localizada y controlada de fármaco anti-progresión de aneurisma
Funding Agency:
Research Group Link:
Materials Engineering (GEMAT)
Vascular Engineering and Applied Biomedicine Group (GEVAB)
Chemical & Synthetic Biology for Biotherapies (ChemSynBio)



Aortyx Receives €2.5 Million Euros from the European Commission’s EIC Accelerator Programme

The IQS spinoff company, Aortyx, has received €2.5 million euros in "Grant first" funding through the European Innovation Council (EIC) Accelerator Programme. Also, Dr Inés Moreno received one of the prestigious Torres Quevedo Grants at the end of 2021 to conduct her research in this spinoff company.

New 3D printer at IQS to manufacture arterial models

The IQS Industrial Products Engineering Laboratory equipment has been expanded with the recent incorporation of the Form 3BL 3D printer, for the manufacture of full-scale polymeric arteries.